 This is a phase IIIa, randomized, double-blind, single-dose, placebo controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age affected with chronic traumatic spinal cord will enter the study with the objective to assess the safety and to obtain efficacy data in intrathecal administration of expanded Whartons jelly mesenchymal stem cells. 